国家医保谈判抗肿瘤药物在常州地区可获得性和可负担性研究

Availability and Affordability of National Medical Insurance Negotiated Innovative Anticancer Drugs in Changzhou

目的了解国家医保谈判抗肿瘤药物在常州地区可获得性和可负担性情况,为后续制定和完善药品使用的政策提供依据。方法采用世界卫生组织(WHO)/国际健康行动组织(HAI)标准调查法,对常州市的国家医疗保险准入谈判新型抗肿瘤药物的可获得性和可负担性进行研究,并分析影响可获得性和可负担性的因素。结果国家医疗保险准入谈判的新型抗肿瘤药物在常州市的总体可获得性较高,可获得的品种数较多,但获得渠道主要集中在公立三级医院;本次调查的新型抗肿瘤药物进入医保后的可负担性显著提高,但仍有较大的提高空间。结论影响因素包括国家政策、医院医疗水平、市场需求、肿瘤流行病特征、仿制药等。建议落实推进国家医疗政策;加强医疗机构管理;发挥零售药店的积极作用,以进一步提高谈判新型抗肿瘤药物的可获得性和可负担性。

Objective To understand the availability and affordability of national medical insurance negotiated innovative anticancer drugs in Changzhou,and to provide evidence for formulating and completing related policy.Methods WHO/HAI standard survey method was adopted to investigate on the availability and affordability of national medical insurance negotiated innovative anticancer drugs in Changzhou,and analyze the factors that affect the results.Results The overall availability of these drugs is really high,with a large number of available varieties,but the access is mainly concentrated in tertiary general hospitals.The affordability of innovative anticancer drugs investigated in this study has been significantly improved after entering medical insurance list,but there is still a large space for improvement.Conclusion The availability and affordability of these drugs were affected by many factors,including policies,the medical level of hospitals,market requirement,characteristics of tumor epidemiology,generics,etc.In order to further improve the availability and affordability of national medical insurance-negotiated innovative anticancer drugs,it is suggested that it is better to implement and promote the national medical policy,strengthen the management of medical and health institutions,and play further positive role of retail pharmacies.